Evidence-based articles on weight loss peptides, dosing protocols, and UK regulations
Retatrutide peptide represents the newest triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, achieving 24.2% average body weight reduction.
Retatrutide dosage begins at 1mg weekly injections for optimal tolerance building. Clinical protocols establish 12mg weekly as the maximum effective dose.
Peptides UK regulations classify therapeutic peptides as prescription-only medicines requiring medical oversight. Research peptides remain legal for laboratory use.
Retatrutide achieves 24.2% average weight loss versus Tirzepatide's 22.5% in comparative trials through triple-receptor activation.
Browse our selection of pharmaceutical-grade peptides
Shop Peptides